Low intensity extracorporeal shockwave therapy for chronic pelvic pain syndrome patients with erectile dysfunction

Abstract

Introduction: In this study, the efficacy of low intensity shock wave therapy (LSWT) in improving symptoms of chronic pelvic pain syndrome (CPPS) and erectile dysfunction (ED) was investigated. Methods: Men diagnosed with CPPS and ED (n = 50) were prescribed with LSWT. The LSWT was administered in 10 sessions over the course of 5 weeks at 3,000 pulses with .25 mJ/mm 2 energy flow and 5 Hz frequency. Outcome parameters were measured before and after LSWT. Results: Clinical symptoms related to CPPS and ED were measured using four validated questionnaires namely National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Index of Erectile Function (IIEF), the International Prostate Symptom Score (IPSS), and Sexual Health Inventory for Men (SHIM). The effect of LSWT on each of the three domains of NIH-CPSI, namely Pain, Symptoms, and Quality of Life (QoL) were also analyzed. Uroflowmetry was measured to assess LSWT effect on urine voiding. The mean baseline CPPS symptoms on NIH-CPSI domains of pain, symptoms and QoL were 9.92 ± 5.72 (mean ± SD), 5.14 ± 14.5, and 8.02 ± 3.17, respectively. LSWT resulted in significant reduction of CPPS symptoms on all NIH-CPSI domains (Pain = .9 ± 1.37; Symptoms = .74 ± 1.03; QoL = 1.16 ± 1.78). The baseline means of CPPS symptoms on IIEF, IPSS, and SHIM were 45.42 ± 16.24, 24.68 ± 9.28, and 14.28 ± 6.02, respectively. LSWT significant improved CPPS symptoms on IIEF (49.48 ± 28.30) and IPSS (9.04 ± 7.01) but not on SHIM (16.02 ± 9.85). No statistically significant differences were observed with all uroflowmetry parameters. Conclusion: The current study demonstrated for the first time the safety and efficacy of LSWT administered in 10 sessions over 5 weeks in improving symptoms of CPPS and ED without causing any significant adverse effect to the patient.

The use of extracorporeal shock wave therapy along with other non-drug methods in the treatment of chronic prostatitis from the standpoint of modern evidence-based medicine

“…Daneshwar и соавт. (2022) [29] исследовали эффективность низкоинтенсивной ЭУВТ (DUOLITH ® SD1 Ultra, Storz Medical AG, Швейцария) в отношении улучшения симптомов ХП/СХТБ (IIIB) и эректильной дисфункции у 50 пациентов в открытом проспективном исследовании. Перед терапией ЭУВТ им назначали антибиотики, α-блокаторы для облегчения симптомов ХП/СХТБ.…”

“…Авторы пришли к выводу, что 10 сеансов ЭУВТ не оказывают существенного влияния на пиковую скорость потока мочи, время опорожнения мочевого пузыря по данным урофлоуметрии, поскольку исходные параметры до лечения были на нормальном уровне. При этом ЭУВТ статистически значимо уменьшает симптомы ХП/СХТБ, улучшает эректильную функцию, качество жизни пациента и не вызывает побочных эффектов [29].…”